Unlock instant, AI-driven research and patent intelligence for your innovation.

Generation of virosome particles

A virion, particle technology, applied in the direction of virus/phage, virus, antiviral agent, etc., can solve the problem of no provision, no suggestion, etc.

Inactive Publication Date: 2013-06-12
FRANVAX
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] The prior art does not provide or suggest a solution to the previously mentioned technical problem of vaccines, especially influenza vaccines, which can be produced in large quantities with high reproducibility and purity and at the same time high immunogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Generation of virosome particles
  • Generation of virosome particles
  • Generation of virosome particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0174] Example 1: Preparation of Virosome Particles

[0175] Influenza hemagglutinin expressed and purified from N. benthamiana dissolved in PBS was mixed with powdered egg-derived lipid (lecithin such as egg yolk lecithin) dissolved in PBS containing 100 mM OEG as a detergent. The lipoprotein ratio can vary from 20:1 to 1:10. In our experiments, the optimal ratio was 6:1. If other lipids (synthetic or steroid types) are used, the lipid-protein ratio can vary even more. Lipid and influenza HA can optionally be subjected to pulses of ultrasound. The mixture was then passed through a 0.22mm filter and passed through a series of different channels in the SM-2 Bio-Bead to remove detergent. Removal of the detergent allows spontaneous assembly of the mixture of dissolved components in the virosome particle population. After the last pass of the SM-2 Bio-Bead, the virion particle population was again subjected to 0.22 mm filtration and the final product was a homogeneous populati...

Embodiment 2

[0176] Example 2: Alternative Modifications of Virosome Particle Production

[0177] Powdered lipid mixtures such as egg-derived phosphatidylcholine and phosphatidylethanolamine were dissolved in PBS containing 100 mM OEG as a detergent. Lipid ratios can vary from 20:1 to 1:10. In our example, the optimal range is 5:1. Lipid ratios can vary from 20:1 to 1:10. In our example, the optimum ratio is 7:1. If other lipids (synthetic or steroid types) are used, the lipid-protein ratio can vary even more. Lipid and influenza HA can optionally be subjected to pulses of ultrasound.

[0178] The solution was then mixed with influenza hemagglutinin expressed and purified from N. benthamiana in PBS. Lipid and influenza HA can optionally be subjected to pulses of ultrasound. The mixture was then passed through a 0.22mm filter and passed through a series of different channels in the SM-2 Bio-Bead to remove detergent. In the final step, the detergent was removed by batch chromatography...

Embodiment 3

[0180] Example 3: Sucrose gradient and silver staining

[0181]Sucrose gradient: By discontinuous ultracentrifugation, a sucrose gradient was used as an analytical method to assess antigen binding in virion particles based on the different densities of individual components. Aliquots of virosome particle preparations in PBS were applied on top of a 10-60% (w / v) discontinuous sucrose gradient in PBS and centrifuged at 100,000 g for 24 h at 4°C. The collected fractions were then analyzed for density and followed by SDS PAGE and silver staining to identify HA-containing fractions.

[0182] Silver staining: SDS PAGE was performed according to the manufacturer's instructions (Invitrogen). Silver staining was performed according to the manufacturer's instructions (Bio-Rad).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the generation of a new class of virosome particles, making use of virus antigens expressed in plant, particularly influenza antigens, and to vaccines, particularly influenza vaccines, containing these virosome particles.

Description

technical field [0001] The present invention relates to the use of viral antigens expressed in plants, especially influenza antigens, for the production of novel virion particles and vaccines, especially influenza vaccines, comprising these virion particles. Background of the invention [0002] Influenza, commonly called the flu, is one of the oldest and most common illnesses. It is an acute respiratory disease characterized by different symptoms like fever, chills, cough, sore throat and headache. It is a true contagious disease transmitted by respiratory secretions through sneezing or coughing. Although influenza is a mild viral infection most of the time, it is also responsible for high morbidity and mortality in infants, the elderly, and adults with compromised immune systems (Cox N.J., Annu Rev Med, 2000, 51: 4-7-421). [0003] Vaccines against influenza are based on influenza virus surface proteins (hemagglutinin, HA), which are protective antigens. Existing influe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/82A61K39/145
CPCA61K39/145A61K2039/5258C12N7/00C12N15/8258C12N2760/16134A61K2039/517A61K39/12A61P31/16A61K9/1271A61K9/1277
Inventor 马里亚·迪纳罗
Owner FRANVAX